

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



Icosabutate

Item No. 19386

Formal Name: 2-[(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-	
eicosapentaen-1-yloxy]-butanoic acid	
Synonyms: PRB 01022, PRC 4016	
MF: $C_{24}H_{38}O_3$	ЭН
FW: 374.6	
Purity: ≥95%	
Supplied as: A solution in ethanol	
Storage: -20°C	
Stability: As supplied, 1 year from the QC date provided on the Certificate of Analysis, when	
stored properly	

Laboratory Procedures

Icosabutate is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of icosabutate in these solvents is approximately 100 mg/ml. Icosabutate is also miscible in ethanol.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of icosabutate is needed, it can be prepared by evaporating the ethanol and directly dissolving the neat oil in aqueous buffers. The solubility of icosabutate in 0.1 M Na₂CO₃ is approximately 1.7 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Icosabutate is a synthetic ω -3 polyunsaturated fatty acid derived from eicosapentaenoic alcohol and 2-bromo butyric acid. It was designed to resist β -oxidation and complex lipid incorporation and increase efficacy in fatty acid-responsive intracellular signaling systems.^{1,2} In a clinical trial, oral administration of icosabutate (600 mg) significantly reduced triglyceride, very low-density lipoprotein cholesterol, and Apo c-III levels in patients with very high triglyceride levels.^{1,2}

References

- 1. Bays, H.E., Hallèn, J., Vige, R., et al. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. J. Clin. Lipidol. 10(1), 181-191 (2016).
- 2. Kastelein, J.J.P., Hallén, J., Vige, R., et al. Icosabutate, a structurally engineered fatty acid, improves the cardiovascular risk profile in statin-treated patients with residual hypertriglyceridemia. Cardiology 135(1), 3-12 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/24/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM